Equities
Health CarePharmaceuticals and Biotechnology
  • Price (DKK)521.40
  • Today's Change-1.80 / -0.34%
  • Shares traded99.63k
  • 1 Year change-5.71%
  • Beta0.5354
Data delayed at least 15 minutes, as of May 23 2022 15:59 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Chr Hansen Holding A/S is a Denmark-based bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. The Company’s business is divided into three divisions, namely Food Cultures & Enzymes, Health & Nutrition and Natural Colors. The Food Cultures & Enzymes division develops and produces cultures, enzymes and probiotics for the food industry in general and the dairy industry in particular. The Health & Nutrition division develops, produces and sells products for the dietary supplement, over-the-counter pharmaceutical, infant formula and animal feed industries. The Natural Colors division develops and supplies natural color solutions to the food and beverage industry, in particular the beverage, confectionery, ice cream, dairy, fruit preparation and prepared food segments. The Company operates in Europe, North and South America, as well as Asia Pacific, Middle East and Africa.

  • Revenue in DKK (TTM)8.52bn
  • Net income in DKK1.65bn
  • Incorporated2004
  • Employees3.95k
  • Location
    Chr Hansen Holding A/SBoege Alle 10-12HOERSHOLM 2970DenmarkDNK
  • Phone+45 45747474
  • Fax+45 45748888
  • Websitehttps://www.chr-hansen.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Johnson Matthey PLC152.04bn1.35bn38.13bn13.56k29.791.7112.280.25080.79220.792289.5513.812.187.908.771,274,336.001.935.373.788.396.807.560.88542.460.77918.640.350745.207.527.90-19.61-9.258.49-0.7396
Azelis Group21.04bn504.19m40.20bn3.18k79.732.4341.681.910.28970.289712.099.53------889,926.00--------22.70--2.48--0.84932.490.3102--27.19---4.52------
Clariant AG28.53bn874.16m43.45bn13.06k49.592.6214.631.520.36542.5011.956.910.52513.946.22298,375.501.972.052.772.9630.8930.823.753.270.817713.560.4635206.68-12.25-7.84261.40-15.77-5.70--
Imcd NV25.56bn1.54bn57.86bn3.74k37.485.3225.912.263.643.6460.3525.641.156.026.31918,516.106.955.649.717.8221.3820.286.034.650.8114.840.433444.4723.8014.9172.5523.2223.7224.12
Oci NV53.04bn6.21bn58.63bn3.72k9.453.143.251.113.963.9633.7811.910.774612.888.471,918,640.0017.221.8327.232.5831.2520.6522.234.151.3013.680.4298--81.8827.08421.0527.71-19.49--
Arkema SA75.75bn11.15bn61.83bn20.20k5.731.223.960.816219.5219.52133.3491.430.83196.116.31527,324.5012.366.6315.128.0723.9521.7814.857.981.3126.210.323827.6720.744.79325.3324.819.627.91
Chr Hansen Holding A/S8.52bn1.65bn68.96bn3.95k42.045.6428.618.0912.4448.2364.4592.710.35923.466.922,159,963.006.9410.128.8612.7356.5057.4019.3121.610.697411.420.376461.3511.072.57-14.211.5714.8320.14
Umicore SA179.00bn4.61bn74.57bn13.64k15.903.1510.380.41662.562.5699.4112.912.778.0513.711,763,651.007.214.8912.038.126.476.512.611.840.883312.690.404935.6116.1518.16374.1927.877.673.83
Akron PAO19.43bn6.62bn78.85bn11.21k11.447.469.794.061,562.541,562.544,595.302,395.290.73542.9921.09--25.348.4035.9812.1759.9047.3434.4615.831.10--0.448981.994.385.43-86.33-26.953.50-19.73
Brenntag SE117.45bn4.47bn80.66bn17.21k18.062.5511.460.68683.893.89102.2027.561.598.366.67915,705.506.215.519.317.6623.1422.243.903.520.980813.040.398141.7221.946.50-3.904.477.506.67
Yara International ASA136.54bn9.71bn87.58bn17.80k9.051.545.400.641552.5352.53739.69309.491.124.238.5610,605,060.007.572.8110.323.5727.1326.576.783.500.7444--0.3365150.2943.367.93-35.02-9.93-12.0023.39
Evonik Industries AG119.77bn6.46bn87.83bn33.15k13.631.166.140.73341.861.8734.5221.840.72324.877.92487,668.203.993.354.974.0126.4728.765.525.130.800329.420.288979.0822.593.2752.970.00-1.540.3454
Novozymes A/S15.55bn3.09bn99.67bn6.64k39.7010.7521.976.4111.0511.0555.5440.790.66212.424.892,513,907.0013.2015.3617.9320.1356.9557.0319.9321.410.755219.290.386446.706.701.1211.360.62170.39176.58
Data as of May 23 2022. Currency figures normalised to Chr Hansen Holding A/S's reporting currency: Danish Krone DKK

Institutional shareholders

18.87%Per cent of shares held by top holders
HolderShares% Held
APG Asset Management NVas of 31 Aug 20216.61m5.01%
Baillie Gifford & Co.as of 19 May 20222.85m2.16%
The Vanguard Group, Inc.as of 05 May 20222.67m2.03%
Walter Scott & Partners Ltd.as of 31 Mar 20222.28m1.73%
Norges Bank Investment Managementas of 31 Dec 20212.04m1.55%
BlackRock Fund Advisorsas of 04 May 20221.89m1.43%
Morgan Stanley Investment Management Co.as of 30 Apr 20221.73m1.32%
GuardCap Asset Management Ltd.as of 31 Mar 20221.69m1.28%
Morgan Stanley Investment Management, Inc.as of 30 Apr 20221.56m1.18%
Impax Asset Management Ltd.as of 31 Mar 20221.55m1.18%
More ▼
Data from 31 Dec 2021 - 31 Mar 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.